These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14555415)

  • 1. A toxicity profile of osteoprotegerin in the cynomolgus monkey.
    Smith BB; Cosenza ME; Mancini A; Dunstan C; Gregson R; Martin SW; Smith SY; Davis H
    Int J Toxicol; 2003; 22(5):403-12. PubMed ID: 14555415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
    Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys.
    Ominsky MS; Kostenuik PJ; Cranmer P; Smith SY; Atkinson JE
    Osteoporos Int; 2007 Aug; 18(8):1073-82. PubMed ID: 17384898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
    Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
    J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
    Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
    J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
    Ma YL; Cain RL; Halladay DL; Yang X; Zeng Q; Miles RR; Chandrasekhar S; Martin TJ; Onyia JE
    Endocrinology; 2001 Sep; 142(9):4047-54. PubMed ID: 11517184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a single dose of osteoprotegerin in postmenopausal women.
    Bekker PJ; Holloway D; Nakanishi A; Arrighi M; Leese PT; Dunstan CR
    J Bone Miner Res; 2001 Feb; 16(2):348-60. PubMed ID: 11204435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading.
    Ichinose Y; Tanaka H; Inoue M; Mochizuki S; Tsuda E; Seino Y
    Calcif Tissue Int; 2004 Oct; 75(4):338-43. PubMed ID: 15549649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
    Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
    Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
    Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of treatment for 3 months with human parathyroid hormone 1-34 peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis).
    Jerome CP; Johnson CS; Lees CJ
    Bone; 1995 Oct; 17(4 Suppl):415S-420S. PubMed ID: 8579946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).
    Sasaki N; Kusano E; Takahashi H; Ando Y; Yano K; Tsuda E; Asano Y
    J Bone Miner Metab; 2005; 23(1):41-7. PubMed ID: 15616893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis).
    Jerome CP; Johnson CS; Vafai HT; Kaplan KC; Bailey J; Capwell B; Fraser F; Hansen L; Ramsay H; Shadoan M; Lees CJ; Thomsen JS; Mosekilde L
    Bone; 1999 Sep; 25(3):301-9. PubMed ID: 10495134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
    Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
    J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients.
    Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Domenig C; Zsontsich T; Klaushofer K; Delling G; Oberbauer R
    Am J Kidney Dis; 2002 Mar; 39(3):580-6. PubMed ID: 11877577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
    Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
    Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.